메뉴 건너뛰기




Volumn 60, Issue 4, 2007, Pages 831-836

Amprenavir and ritonavir plasma concentrations in HIV-infected patients treated with fosamprenavir/ritonavir with various degrees of liver impairment

Author keywords

Cirrhosis; HBV; HCV; Pharmacokinetics

Indexed keywords

AMPRENAVIR PHOSPHATE; AMPRENAVIR PHOSPHATE PLUS RITONAVIR; BILIRUBIN; PROTEINASE INHIBITOR; RITONAVIR; UNCLASSIFIED DRUG;

EID: 34548706470     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm282     Document Type: Article
Times cited : (16)

References (18)
  • 1
    • 0034020556 scopus 로고    scopus 로고
    • Single-dose pharmacokinetics of amprenavir, a human immunodeficiency virus type 1 protease inhibitor, in subjects with normal or impaired hepatic function
    • Veronese L, Rautaureau J, Sadler BM et al. Single-dose pharmacokinetics of amprenavir, a human immunodeficiency virus type 1 protease inhibitor, in subjects with normal or impaired hepatic function. Antimicrob Agents Chemother 2000; 44: 821-6.
    • (2000) Antimicrob Agents Chemother , vol.44 , pp. 821-826
    • Veronese, L.1    Rautaureau, J.2    Sadler, B.M.3
  • 2
    • 0032741963 scopus 로고    scopus 로고
    • Saquinavir therapy in patients with advanced HIV infection and liver cirrhosis
    • Tachikawa N, Yoshizawa S, Kikuchi Y et al. Saquinavir therapy in patients with advanced HIV infection and liver cirrhosis. Jpn J Infect Dis 1999; 52: 177-8.
    • (1999) Jpn J Infect Dis , vol.52 , pp. 177-178
    • Tachikawa, N.1    Yoshizawa, S.2    Kikuchi, Y.3
  • 3
    • 19944432901 scopus 로고    scopus 로고
    • Clinical pharmacokinetics of nelfinavir and its metabolite M8 in human immunodeficiency virus (HIV)-positive and HIV-hepatitis C virus-coinfected subjects
    • Regazzi M, Maserati R, Villani P et al. Clinical pharmacokinetics of nelfinavir and its metabolite M8 in human immunodeficiency virus (HIV)-positive and HIV-hepatitis C virus-coinfected subjects. Antimicrob Agents Chemother 2005; 49: 643-9.
    • (2005) Antimicrob Agents Chemother , vol.49 , pp. 643-649
    • Regazzi, M.1    Maserati, R.2    Villani, P.3
  • 5
    • 0034606721 scopus 로고    scopus 로고
    • Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection
    • Sulkowski MS, Thomas DL, Chaisson RE et al. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000; 283: 74-80.
    • (2000) JAMA , vol.283 , pp. 74-80
    • Sulkowski, M.S.1    Thomas, D.L.2    Chaisson, R.E.3
  • 6
    • 0032945886 scopus 로고    scopus 로고
    • Simultaneous determination of the HIV-protease inhibitors indinavir, nelfinavir, saquinavir and ritonavir in human plasma by reversed-phase high-performance liquid chromatography
    • Hugen PW, Verweij-van Wissen CP, Burger DM et al. Simultaneous determination of the HIV-protease inhibitors indinavir, nelfinavir, saquinavir and ritonavir in human plasma by reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 1999; 727: 139-49.
    • (1999) J Chromatogr B Biomed Sci Appl , vol.727 , pp. 139-149
    • Hugen, P.W.1    Verweij-van Wissen, C.P.2    Burger, D.M.3
  • 7
    • 0034469255 scopus 로고    scopus 로고
    • Bioanalylicall method validation - a revisit with a decade of progress
    • Shah VP, Midha KK, Findlay JWA et al. Bioanalylicall method validation - a revisit with a decade of progress. Pharm Res 2000; 17: 1551-7.
    • (2000) Pharm Res , vol.17 , pp. 1551-1557
    • Shah, V.P.1    Midha, K.K.2    Findlay, J.W.A.3
  • 8
    • 9144240623 scopus 로고    scopus 로고
    • Six-week randomized controlled trial to compare the tolerabilities, pharmacokinetics, and antiviral activities of GW433908 and amprenavir in human immunodeficiency virus type 1-infected patients
    • Wood R, Arasteh K, Stellbrink HJ et al. Six-week randomized controlled trial to compare the tolerabilities, pharmacokinetics, and antiviral activities of GW433908 and amprenavir in human immunodeficiency virus type 1-infected patients. Antimicrob Agents Chemother 2004; 48: 116-23.
    • (2004) Antimicrob Agents Chemother , vol.48 , pp. 116-123
    • Wood, R.1    Arasteh, K.2    Stellbrink, H.J.3
  • 9
    • 0035115820 scopus 로고    scopus 로고
    • 1-acid glycoprotein on pharmacokinetics of amprenavir, a human immunodeficiency virus protease inhibitor
    • 1-acid glycoprotein on pharmacokinetics of amprenavir, a human immunodeficiency virus protease inhibitor. Antimicrob Agents Chemother 2001; 45 852-6.
    • (2001) Antimicrob Agents Chemother , vol.45 , pp. 852-856
    • Sadler, B.M.1    Gillotin, C.2    Lou, Y.3
  • 10
    • 34548783469 scopus 로고    scopus 로고
    • Norvir (ritonavir, Prescribing information USA, North Chicago, IL: Abbott Laboratories
    • Norvir (ritonavir). Prescribing information (USA). North Chicago, IL: Abbott Laboratories.
  • 11
    • 33644645264 scopus 로고    scopus 로고
    • Pharmacokinetic and safety evaluation of high-dose combinations of fosamprenavir and ritonavir
    • Shelton MJ, Wire MB, Lou Y et al. Pharmacokinetic and safety evaluation of high-dose combinations of fosamprenavir and ritonavir. Antimicrob Agents Chem 2006; 50: 928-34.
    • (2006) Antimicrob Agents Chem , vol.50 , pp. 928-934
    • Shelton, M.J.1    Wire, M.B.2    Lou, Y.3
  • 13
    • 34548751973 scopus 로고    scopus 로고
    • Peng J, Bertz R, Hsu A et al. Evaluation of single and multiple dose pharmacokinetics of ritonavir in subjects with mild or moderate hepatic insufficiency. In: Abstracts of the Fourth International Workshop on Clinical Pharmacology of HIV Therapy, Cannes, France, 2003 Abstract 16, p.3.7.
    • Peng J, Bertz R, Hsu A et al. Evaluation of single and multiple dose pharmacokinetics of ritonavir in subjects with mild or moderate hepatic insufficiency. In: Abstracts of the Fourth International Workshop on Clinical Pharmacology of HIV Therapy, Cannes, France, 2003 Abstract 16, p.3.7.
  • 14
    • 0036294598 scopus 로고    scopus 로고
    • Effect of interferon α-ribavirin biotherapy on cytochrome P450 1A2 and 2D6 and N-acetyltransterase-2 activities in patients with chronic active hepatitis C
    • Becquerhont L, Chazouilleres O, Serfaty L et al. Effect of interferon α-ribavirin biotherapy on cytochrome P450 1A2 and 2D6 and N-acetyltransterase-2 activities in patients with chronic active hepatitis C. Clin Pharm Ther 2002; 71: 488-95.
    • (2002) Clin Pharm Ther , vol.71 , pp. 488-495
    • Becquerhont, L.1    Chazouilleres, O.2    Serfaty, L.3
  • 15
    • 32944457844 scopus 로고    scopus 로고
    • Pharmacokinetics of lopinavir/ritonavir in HIV/hepatitis C virus-coinfected subjects with hepatic impairment
    • Peng JZ, Pulido F, Causemaker SJ et al. Pharmacokinetics of lopinavir/ritonavir in HIV/hepatitis C virus-coinfected subjects with hepatic impairment. J Clin Pharmacol 2006; 46: 265-74.
    • (2006) J Clin Pharmacol , vol.46 , pp. 265-274
    • Peng, J.Z.1    Pulido, F.2    Causemaker, S.J.3
  • 16
    • 10244222704 scopus 로고    scopus 로고
    • Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir
    • Sulkowski MS, Mehta SH, Chaisson RE et al. Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir. AIDS 2004; 18: 2277-84.
    • (2004) AIDS , vol.18 , pp. 2277-2284
    • Sulkowski, M.S.1    Mehta, S.H.2    Chaisson, R.E.3
  • 17
    • 27944467897 scopus 로고    scopus 로고
    • Is there evidence for an increase in the death rate from liver-related disease in patients with HIV?
    • Mocroft A, Soriano V, Rockstroh J et al. Is there evidence for an increase in the death rate from liver-related disease in patients with HIV? AIDS 2005; 19: 2117-25.
    • (2005) AIDS , vol.19 , pp. 2117-2125
    • Mocroft, A.1    Soriano, V.2    Rockstroh, J.3
  • 18
    • 14744286600 scopus 로고    scopus 로고
    • Pharmacokinetics and hepatotoxicity of lopinavir/ritonavir in non-cirrhotic HIV and hepatitis C virus (HCV) co-infected patients
    • Canta F, Marrone R, Bonora et al. Pharmacokinetics and hepatotoxicity of lopinavir/ritonavir in non-cirrhotic HIV and hepatitis C virus (HCV) co-infected patients. J Antimicrob Chemother 2005; 55: 280-1.
    • (2005) J Antimicrob Chemother , vol.55 , pp. 280-281
    • Canta, F.1    Marrone, R.2    Bonora3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.